摘要
目的探讨巴曲酶与阿司匹林联合治疗急性脑梗死的疗效和安全性。方法将93例确诊为急性脑梗死患者按住院的先后顺序,按随机数字表平均分成3组,分别检测治疗前后血小板计数、血小板聚集率、纤维蛋白原、高切应力、红细胞比容、血栓烷B2(TXB2)、出血(包括颅内出血及其它脏器出血)的发生率,并进行统计分析。结果单用阿司匹林组(ASA组n=31)、单用巴曲酶组(巴曲酶组n=31)及两者联合治疗组(联合治疗组n=31)患者的性别、年龄、体重差异均无显著性(均P>0.05)。治疗1周后血小板聚集率、血栓烷B2(TXB2)、纤维蛋白原、高切应力指标的均数3组不全相同,对血小板聚集率和纤维蛋白原指标的均数两两比较后显示,联合治疗组血小板聚集率明显低于两种单药治疗组(P<0.01);巴曲酶组和联合治疗组血纤维蛋白原明显低于ASA组(P<0.01);出血发生率3组之间比较差异无显著性(P>0.05)。结论巴曲酶联合阿司匹林治疗急性脑梗死疗效优于单药治疗,且安全性好。
Objective To investigate the effect and safety of Batroxobin（DF-521） combined with Asirin（ASA） in the treatment of acute cerebral infarction.Methods 93 patients with acute cerebral infarction who confirmed in hospital were randomly divided into 3 groups,platelet counts were measured before and after treatment,platelet aggregation,fibrinogen,high shear stress,hematocrit,thromboxaneB2（TXB2）,the incidence of bleeding（including intracranial hemorrhage and other organs,bleeding） were all observed and statistical analysis were made.Results There was no significant difference between patient′s sex,age,body weight among ASA group（n=31）,Batroxobin group（n=31） and ASA combined with Batroxobin group（n=31）（P0.05）.After 1 week treatment,Platelet count,blood viscosity,platelet aggregation test（PAgT）,fibrinogen,coagulation studies（PT,APTT,INR）,TXB2 were not entire same in 3 groups.Platelet aggregation and fibrinogen in the mean pairwise comparison showed that the combination group was significantly lower than both platelet aggregation monotherapy group（P0.01）;Batroxobin group and combined group was significantly lower than fibrinogen ASA group（P0.01）.The incidence of bleeding among the 3 groups was not significant difference（P0.05）.Conclusion ASA combined with Batroxobin shows better clinical effect and less hemorrhagic risk than ASA or Batroxobin in the therapy of acute cerebral infarction.
出处
《黑龙江医学》
2011年第3期178-180,共3页
Heilongjiang Medical Journal
关键词
急性脑梗死
巴曲酶
阿司匹林
联合治疗
Acute cerebral infarction
Batroxobin
Aspirin
Combined treatment
